Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Authors
Keywords
-
Journal
mAbs
Volume 5, Issue 1, Pages 22-33
Publisher
Informa UK Limited
Online
2013-01-17
DOI
10.4161/mabs.22771
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes
- (2014) F. Perosa et al. JOURNAL OF IMMUNOLOGY
- Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
- (2012) M. S. Czuczman et al. BLOOD
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
- (2012) Myron S. Czuczman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
- (2012) Andres Forero-Torres et al. CLINICAL CANCER RESEARCH
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) M. Dreyling et al. ANNALS OF ONCOLOGY
- Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Radioimmunotherapy in follicular lymphoma
- (2011) Tim Illidge et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- CD20 antibodies: doing the time warp
- (2011) M. S. Cragg BLOOD
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
- (2011) S. H. Lim et al. BLOOD
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) H. Tilly et al. ANNALS OF ONCOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma
- (2010) Lan Wu et al. CANCER LETTERS
- U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
- (2010) S. J. Lemery et al. CLINICAL CANCER RESEARCH
- Rituximab
- (2010) Gillian M. Keating DRUGS
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
- (2010) Marinus H.J. van Oers et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
- (2010) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
- (2009) B. Li et al. BLOOD
- A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults
- (2009) P. Bartolucci et al. BLOOD
- Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
- (2009) Susumu Uchiyama et al. CANCER SCIENCE
- CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
- (2009) M. S. Hayden-Ledbetter et al. CLINICAL CANCER RESEARCH
- CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
- (2009) N. A. Johnson et al. HAEMATOLOGICA
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
- (2009) Jiamu Du et al. MOLECULAR IMMUNOLOGY
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
- (2008) D. M. Goldenberg et al. BLOOD
- Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
- (2008) S. A. Beers et al. BLOOD
- CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor
- (2008) Maria J. Polyak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
- (2008) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide
- (2008) Jiamu Du et al. MOLECULAR IMMUNOLOGY
- Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
- (2008) Manzurul A. Sikder et al. Current Hematologic Malignancy Reports
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started